Recent Updates
Recently added Catalysts

Atovaquone/Proguanil

Phase 2

Malaria, Falciparum | Small molecule | Infectious Disease |Pfizer, Inc.|Last Updated: May 11, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment244
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00084227Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South AmericaPHASE2 COMPLETED 244Jul 1, 2004Jul 1, 2005May 11, 2011 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
parasite clearance
Secondary Endpoints
tolerability and safety
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
Azithromycin/ChloroquineDRUG -
Atovaquone/ProguanilDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Written informed consent of the subject or a legally authorized representative * Females and males \>= 18 years of age with uncomplicated, symptomatic malaria as indicated by the presence of both of the following: a.) Blood smears positive for Plasmodium falciparum asexual par...

Unlock Eligibility Criteria